Drug Profile
Research programme: neurological disorders - Oxford GlycoSciences
Latest Information Update: 24 Sep 2007
Price :
$50
*
At a glance
- Originator Oxford GlycoSciences
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bipolar disorders; Schizophrenia; Vascular dementia
Most Recent Events
- 07 Aug 2003 Oxford GlycoSciences has been acquired by Celltech Group
- 27 Apr 2000 Preclinical development for Bipolar disorders in England (Unknown route)
- 27 Apr 2000 Preclinical development for Schizophrenia in England (Unknown route)